Mycophenolate mofetil NDC 23155-830

NDC codes

FDA NDC Directory

Product NDC (as listed)23155-830Labeler and product segments. Claims need a package NDC.

Product NDC at billing width23155-0830Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
23155-830-01	23155083001	100 CAPSULE in 1 BOTTLE, PLASTIC (23155-830-01)Marketed from Jun 30, 2022
23155-830-05	23155083005	500 CAPSULE in 1 BOTTLE, PLASTIC (23155-830-05)Marketed from Jun 30, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Mycophenolate mofetil
Generic name (nonproprietary): mycophenolate mofetil
Active ingredients: Mycophenolate mofetil — 250 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090055
Marketing start: Jun 30, 2022
Marketing end: May 31, 2028
Identifiers: Product ID 23155-830_4c6ca7cd-80b3-4703-904c-6d6d78965f4bSPL ID 4c6ca7cd-80b3-4703-904c-6d6d78965f4bSPL set ID 3ac54299-15cc-4c7a-8831-60c15a859b85RxCUI 199058, 200060UNII 9242ECW6R0UPC 0323155830019, 0323155836059
Pharmacologic class: Antimetabolite Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N423155083001 followed by a unit qualifier and the quantity

Package 23155-0830-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 26, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Mycophenolate mofetil (MMF) is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies ( 14.1 )] , heart [see Clinical Studies ( 14.2 )] or liver transplants [see Clinical Studies ( 14.3 )] , in combination with other immunosuppressants. Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 090055

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090055
Product	Strength	Form · route	Labeler	Product NDC
Mycophenolate mofetil	Mycophenolate mofetil 250 mg/1	CapsuleOral	REMEDYREPACK INC.	70518-3799
Mycophenolate mofetil	Mycophenolate mofetil 250 mg/1	CapsuleOral	Strides Pharma Science Limited	64380-726
Mycophenolate mofetil	Mycophenolate mofetil 250 mg/1	CapsuleOral	AvKARE	73190-009
Mycophenolate mofetil	Mycophenolate mofetil 250 mg/1	CapsuleOral	Strides Pharma Inc.	42543-988